Bingyu Lin

Discussion SPMs following CAR-T therapy have garnered global attention; however, the risk of SPMs associated with BsAb—a promising alternative to CAR-T with similar mechanisms of action and targets—remains underexplored. To address this gap, we conducted the first comprehensive analysis of SPMs following BsAbs therapy using large-scale, real-world data from the FAERS database, and performed a detailed comparison of SPM profiles between BsAbs and CAR-T treatments.

Immune cell therapies and immune cell engineering Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

X. Wang, L. Li, T. Zhang, B. Lin, J. Ni, C. Au and L. Jiang, Chem. Commun., 2019, Advance Article , DOI: 10.1039/C8CC07130F If you are not the author of this article and you wish to reproduce material from it in a third party non-RSC publication you must formally request permission using Copyright Clearance Center. Go to our Instructions for using Copyright Clearance Center page for details.